|
| Pronunciation |
 (mo
EKS i pril & hye droe klor oh
THYE a zide) |
 |
| U.S. Brand Names |
| Uniretic™ |
|
| Generic Available |
|
No |
|
| Pharmacological Index |
|
Antihypertensive Agent, Combination |
|
| Use |
|
Combination therapy for hypertension, however, not indicated for initial treatment of hypertension; replacement therapy in patients receiving separate dosage forms (for patient convenience); when monotherapy with one component fails to achieve desired antihypertensive effect, or when dose-limiting adverse effects limit upward titration of monotherapy |
|
| Pregnancy Risk Factor |
|
C/D (2nd and 3rd trimesters) |
|
| Adverse Reactions |
|
See individual agents |
|
| Drug Interactions |
|
See individual agents |
|
| Mechanism of Action |
|
See individual agents |
|
| Usual Dosage |
|
Adults: Oral: 7.5-30 mg of moexipril, taken either in a single or divided dose one hour before meals |
|
| Cardiovascular Considerations |
|
Combination therapy for the treatment of hypertension should be individualized for each patient. Potential advantages for moexipril and hydrochlorothiazide combination therapy may include improved compliance and synergistic reductions in blood pressure with an accompanied reduction in side effects. ACE inhibitors and thiazides are also standard therapy for left ventricular systolic dysfunction. |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
See individual agents. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to be pregnant. Consult prescriber if breast-feeding. |
|
| Dosage Forms |
|
Tablet: Moexipril hydrochloride 7.5 mg and hydrochlorothiazide 12.5 mg; moexipril hydrochloride 15 mg and hydrochlorothiazide 25 mg |
|
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
